Trial · NCT07898150
Registered outcomes26
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 26
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Recruitment Rate | During study enrolment | The number of participants that consent given the number of potential participants that are approached about the study, expressed as a percentage. |
| Primary | Intervention Adherence | Collected at the end of the intervention (Week 4). | The number of intervention sessions attended by participants compared to the anticipated number of sessions, expressed as a percentage. |
| Primary | Attrition Rate | Collected at the end of the intervention (Week 4). | The number of participants who are withdrawn from the study or drop out, expressed as a percentage of the total sample. |
| Primary | Adverse Events | Collected throughout the intervention period with final reporting at the end of the intervention (Week 4). | An Adverse Event reporting form will be used to track the number, type, and severity of adverse events. This data will be reported descriptively. |
| Primary | Feasibility Survey | Collected at the end of the intervention (Week 4). | All participants will complete a survey about the use of TSS during their therapy. This survey uses a 7-point Likert scale (strongly disagree to strongly agree) to score a total of 13 items, meaning the minimum score would be 13, indicating low feasibility, and the maximum score would be 91, indicating high feasibility. The findings will be reported descriptively. |
| Primary | Semi-Structured Interview | Collected at the end of the intervention (Week 4). | A semi-structured interview will ask participants for their perspectives on the intervention. The data will be reported qualitatively. |
| Secondary | Session Time | Collected throughout the intervention period with final reporting at the end of the intervention (Week 4). | Time spent in each session, along with time using TSS. Measured in minutes. |
| Secondary | Distance Travelled | Collected throughout the intervention period with final reporting at the end of the intervention (Week 4). | For participants using the FES bike, measured in meters. |
| Secondary | Asymmetry Output | Collected throughout the intervention period with final reporting at the end of the intervention (Week 4). | For participants using the FES bike, measured as percentage of time using the right and left legs. |
| Secondary | Time Off Motor Support | Collected throughout the intervention period with final reporting at the end of the intervention (Week 4). | For participants using the FES bike, measured as percentage of time spent in active compared to passive cycling. |
| Secondary | Energy | Collected throughout the intervention period with final reporting at the end of the intervention (Week 4). | For participants using the FES bike, measured as kilocalories per hour. |
| Secondary | Power | Collected throughout the intervention period with final reporting at the end of the intervention (Week 4). | For participants using the FES bike, measured as average Watts over each session. |
| Secondary | Velocity | Collected throughout the intervention period with final reporting at the end of the intervention (Week 4). | For participants using the FES bike, measured as average revolutions per minute (RPM) over each session. |
| Secondary | Standing and Walking Assessment Tool (SWAT) | Collected at baseline and at the end of the intervention (Week 4). | For participants in inpatient rehabilitation. Standardized functional scale. Lowest functional stage of 0 (inability to stand) and highest functional stage of 4 (unimpaired community walking). |
| Secondary | Berg Balance Scale | Collected at baseline and at the end of the intervention (Week 4) as appropriate. | For participants in inpatient rehabilitation in SWAT stages 1-4. Standardized scale with 14 items scored from 0 to 4, with a minimum score of 0, indicating the lowest level of function, and a maximum score of 52, indicating the highest functional level. |
| Secondary | Modified Timed-Up-and-Go | Collected at baseline and at the end of the intervention (Week 4) as appropriate. | For participants in inpatient rehabilitation in SWAT stages 2-4. Measured in time taken to complete (seconds). |
| Secondary | 10 Meter Walk Test | Collected at baseline and at the end of the intervention (Week 4) as appropriate. | For participants in inpatient rehabilitation in SWAT stages 2-4. Measured in time taken to complete which is converted to walking speed (meters per second). |
| Secondary | Six Minute Walk Test | Collected at baseline and at the end of the intervention (Week 4) as appropriate. | For participants in inpatient rehabilitation in SWAT stages 3-4. Measured in total distance walked (meters). |
| Secondary | Activities-specific Balance Confidence Scale | Collected at baseline and at the end of the intervention (Week 4) as appropriate. | For participants in inpatient rehabilitation in SWAT stages 2-4. Standardized scale with 16 items scored from 0 to 100 and then averaged, with a minimum score of 0, indicating the lowest level of confidence, and a maximum score of 100, indicating the highest confidence level. |
| Secondary | Manual Muscle Testing | Collected at baseline and at the end of the intervention (Week 4). | For participants in inpatient rehabilitation. Standardized scale with 16 muscles scored from 0 (no muscle activation) to 5 (full strength against resistance) bilaterally. Total scores for the upper and lower extremity summed. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07898150/registered